12:00 AM
Jun 01, 2015
 |  BC Week In Review  |  Clinical News  |  Clinical Results

CX-01: Phase I data

An open-label, U.S. Phase I trial in 12 AML patients showed that induction chemotherapy consisting of cytarabine and idarubicin plus CX-01 as a continuous infusion for 7 days following a bolus led to morphologic complete remission after 1 induction in 11 patients. One patient relapsed 6 months after...

Read the full 220 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >